[FOR INVESTORS AND MEDIA] The FDA has granted Breakthrough Therapy designation to BPL-003 for treatment-resistant depression. This milestone validates our strong Phase 2b data and accelerates our path forwards to Phase 3. beckleypsytech.com/posts/ata…